Target intelligence / Profile preview

Gut microbiota ecosystem (GM) (GM)

Target
GM
Molecular classification
Other
01

Overview

The gut microbiota ecosystem is a complex, dynamic community of trillions of microorganisms, including bacteria, fungi, archaea, and viruses, that reside primarily in the large intestine (Source: Nature Reviews Microbiology, 2022). This ecological community functions as a "forgotten organ," performing vital roles in nutrient metabolism, the synthesis of essential vitamins like K and B12, and the maturation of the host's immune system (Source: NIH, 2023). It also provides colonization resistance against pathogens by competing for nutrients and attachment sites (Source: Cell, 2021). Dysbiosis, characterized by a loss of microbial diversity or an overgrowth of pathogenic species, is strongly associated with local gastrointestinal disorders like Clostridioides difficile infection and inflammatory bowel disease (Source: PubMed, 2021). Furthermore, imbalances in the gut microbiota are linked to systemic conditions such as obesity, type 2 diabetes, and even neurodegenerative diseases via the gut-brain axis (Source: Nature, 2020). Therapeutic strategies targeting this ecosystem range from broad-spectrum antibiotics and probiotics to advanced live biotherapeutic products (LBPs) and fecal microbiota transplantations (Source: FDA, 2023). These interventions, such as the recently approved Vowst and Rebyota, aim to restore homeostatic balance and enhance the production of bioactive metabolites like short-chain fatty acids (Source: Seres Therapeutics, 2023).

Other names
Gut microbiomeIntestinal microbiotaGastrointestinal floraGut microfloraHuman intestinal tract ecosystem
02

Mechanism of action

Restoration of microbial diversity and ecological balance to suppress pathogen overgrowth and modulate host physiological processes (Source: Nature Reviews Microbiology, 2022).

03

Biological functions

Immune responseOther
04

Disease associations

InfectionInflammationOther
05

Safety considerations

Transmission of multi-drug resistant organismsRisk of bacteremia in immunocompromised patientsUnpredictable long-term immunological shiftsLack of standardization in live biotherapeutic products (Source: FDA, 2023)
06

Interacting drugs

SER-109 (Vowst)

6 more in the full profile.

07

Biomarkers

Alpha diversity indexFirmicutes/Bacteroidetes ratioShort-chain fatty acid levels16S rRNA sequencing profiles

Beyond the preview

Go deeper on Gut microbiota ecosystem (GM) (GM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gut microbiota ecosystem (GM) (GM).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call